Cargando…

Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis

OBJECTIVE: To analyze the clinical characteristics, prognosis and parallel clinical course of ovarian cancer (OC) and dermatomyositis (DM). METHODS: The medical records of 23 consecutive patients who were diagnosed with OC and DM and were treated at Peking Union Medical College Hospital (PUMCH) betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Hongyan, Huo, Lanqing, Wang, Dan, Xiang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779614/
https://www.ncbi.nlm.nih.gov/pubmed/31576691
http://dx.doi.org/10.3802/jgo.2019.30.e99
_version_ 1783456939475206144
author Cheng, Hongyan
Huo, Lanqing
Wang, Dan
Xiang, Yang
author_facet Cheng, Hongyan
Huo, Lanqing
Wang, Dan
Xiang, Yang
author_sort Cheng, Hongyan
collection PubMed
description OBJECTIVE: To analyze the clinical characteristics, prognosis and parallel clinical course of ovarian cancer (OC) and dermatomyositis (DM). METHODS: The medical records of 23 consecutive patients who were diagnosed with OC and DM and were treated at Peking Union Medical College Hospital (PUMCH) between 2002 and 2017 were reviewed. Propensity score matching method was used to match control group (OC patients without DM) at a ratio of 1:5. The correlation between OC and DM was measured using the Pearson correlation scatter plot and Pearson's r. Kaplan-Meier survival analysis and Cox proportional hazard regression analysis were performed to evaluate the prognostic factors. RESULTS: After matching, 23 patients who have the concurrence of OC and DM (DM group) and 115 patients diagnosed with OC alone (No DM group) were included. The 5-year overall survival rates (71.6% vs. 51.8%, p=0.020) and 5-year progression-free survival (30.5% vs. 0%, p=0.018) were poorer in DM group. Correlation between serum cancer antigen 125 (CA 125) and creatine kinase (CK) level was observed in 12 patients. The time between OC and DM diagnosis is significant through univariable analysis (p=0.021) but not in multivariable analysis in patients who have the concurrence of OC and DM. CONCLUSION: The concurrence of OC and DM as a paraneoplastic syndrome is rare and has a poor prognosis. The risk for patients diagnosed with DM is highest within 3 years before or after OC diagnosis. A correlation and a parallel clinical course exist between these 2 diseases.
format Online
Article
Text
id pubmed-6779614
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-67796142019-11-01 Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis Cheng, Hongyan Huo, Lanqing Wang, Dan Xiang, Yang J Gynecol Oncol Original Article OBJECTIVE: To analyze the clinical characteristics, prognosis and parallel clinical course of ovarian cancer (OC) and dermatomyositis (DM). METHODS: The medical records of 23 consecutive patients who were diagnosed with OC and DM and were treated at Peking Union Medical College Hospital (PUMCH) between 2002 and 2017 were reviewed. Propensity score matching method was used to match control group (OC patients without DM) at a ratio of 1:5. The correlation between OC and DM was measured using the Pearson correlation scatter plot and Pearson's r. Kaplan-Meier survival analysis and Cox proportional hazard regression analysis were performed to evaluate the prognostic factors. RESULTS: After matching, 23 patients who have the concurrence of OC and DM (DM group) and 115 patients diagnosed with OC alone (No DM group) were included. The 5-year overall survival rates (71.6% vs. 51.8%, p=0.020) and 5-year progression-free survival (30.5% vs. 0%, p=0.018) were poorer in DM group. Correlation between serum cancer antigen 125 (CA 125) and creatine kinase (CK) level was observed in 12 patients. The time between OC and DM diagnosis is significant through univariable analysis (p=0.021) but not in multivariable analysis in patients who have the concurrence of OC and DM. CONCLUSION: The concurrence of OC and DM as a paraneoplastic syndrome is rare and has a poor prognosis. The risk for patients diagnosed with DM is highest within 3 years before or after OC diagnosis. A correlation and a parallel clinical course exist between these 2 diseases. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2019-06-10 /pmc/articles/PMC6779614/ /pubmed/31576691 http://dx.doi.org/10.3802/jgo.2019.30.e99 Text en Copyright © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Cheng, Hongyan
Huo, Lanqing
Wang, Dan
Xiang, Yang
Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
title Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
title_full Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
title_fullStr Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
title_full_unstemmed Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
title_short Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
title_sort concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779614/
https://www.ncbi.nlm.nih.gov/pubmed/31576691
http://dx.doi.org/10.3802/jgo.2019.30.e99
work_keys_str_mv AT chenghongyan concurrenceofovariancanceranddermatomyositisapropensityscoreanalysis
AT huolanqing concurrenceofovariancanceranddermatomyositisapropensityscoreanalysis
AT wangdan concurrenceofovariancanceranddermatomyositisapropensityscoreanalysis
AT xiangyang concurrenceofovariancanceranddermatomyositisapropensityscoreanalysis